DCM
NVO

Dupont Capital Management’s Novo Nordisk NVO Stock Holding History

Dupont Capital Management’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-21,642
Closed -$1.46M – 1062
2022
Q4 		$1.46M Buy
+21,642
New +$1.27M 0.07% 235

Other funds holding NVO

Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Fayez Sarofim & Co
Fayez Sarofim & Co Houston, Texas $39.1B AUM 15.14% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return

Dupont Capital Management's NVO Position: Q1 2023 in Review

Dupont Capital Management sold out of Novo Nordisk (NVO) in Q1 2023, closing a stake of 21,642 shares — an estimated $1.46M sold.

Dupont Capital Management first reported a position in NVO in Q4 2022 and held it in 1 quarter. The position peaked at $1.46M in Q4 2022. 1,146 funds tracked by Wall St. Rank hold NVO as of Q1 2023.

  • Dupont Capital Management reported no remaining Novo Nordisk position as of Q1 2023 after selling out during the quarter.
  • Dupont Capital Management sold 21,642 Novo Nordisk shares in Q1 2023, an estimated $1.46M.
  • Dupont Capital Management first reported a position in Novo Nordisk in Q4 2022 and held it in 1 quarter.
  • Dupont Capital Management's Novo Nordisk position peaked at $1.46M in Q4 2022.
  • 1,146 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2023.

Based on Dupont Capital Management's 13F filing for Q1 2023, filed 28 Apr 2023.